Last quarter (Q4 2022), Scinai Immunotherapeutics's total revenue was ₪―, a decrease of ― from the same quarter last year. In Q4, Scinai Immunotherapeutics's net income was ₪3.52M. See Scinai Immunotherapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	₪ 7.17M	-	₪ 0.00	₪ 0.00	₪ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	₪ 7.17M	-	-	-	-
Operating Expense	₪ 3.73M	₪ 11.06M	₪ 10.87M	₪ -7.33M	₪ 78.35M	₪ 77.07M
Operating Income	₪ -3.73M	₪ -11.06M	₪ -10.87M	₪ 7.33M	₪ -78.35M	₪ -77.07M
Net Non Operating Interest Income Expense	₪ -1.86M	₪ 5.26M	₪ 2.66M	₪ -11.79M	₪ -30.84M	₪ -13.50M
Other Income Expense	-	₪ -10.37M	₪ -12.00K	₪ -10.63M	₪ -15.77M	₪ 2.84M
Pretax Income	₪ -5.59M	₪ -5.80M	₪ -8.21M	₪ -4.46M	₪ -109.19M	₪ -87.73M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	₪ -5.59M	₪ -5.80M	₪ -8.21M	₪ -4.46M	₪ -109.19M	₪ -87.73M
Basic EPS	₪ -0.80	₪ -0.01	₪ -0.20	₪ -0.40	₪ -13.20	₪ -13.60
Diluted EPS	₪ -0.80	₪ -0.01	-	₪ -0.40	₪ -13.20	₪ -13.60
Basic Average Shares	₪ 1.31B	₪ 754.08M	₪ 56.46M	₪ 11.08M	₪ 8.17M	₪ 6.54M
Diluted Average Shares	₪ 1.31B	₪ 754.08M	₪ 64.28M	₪ 11.08M	₪ 8.17M	₪ 6.54M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	₪ 313.00K	₪ 323.00K	₪ 343.00K
Total Expenses	₪ 3.73M	₪ 11.06M	₪ 10.87M	₪ -7.33M	₪ 78.35M	₪ 77.07M
Net Income From Continuing And Discontinued Operation	₪ -12.62M	₪ -5.80M	₪ -8.21M	₪ -4.46M	₪ -109.19M	₪ -87.73M
Normalized Income	₪ -9.11M	-	-	₪ -4.46M	₪ -109.19M	₪ -90.56M
Interest Expense	₪ 9.81M	-	-	₪ 15.63M	₪ 30.85M	₪ 13.54M
EBIT	₪ 4.22M	₪ -5.80M	₪ -8.21M	₪ 11.18M	₪ -78.35M	₪ -74.18M
EBITDA	₪ 5.13M	₪ -5.08M	₪ -7.59M	₪ 13.61M	₪ -76.70M	₪ -73.92M

Currency in ILS

Scinai Immunotherapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing